Literature DB >> 22150316

Inhibition of Mycobacterium tuberculosis-induced signalling by transforming growth factor-β in human mononuclear phagocytes.

M Wu1, H Aung, C S Hirsch, Z Toossi.   

Abstract

Tuberculosis (TB) is associated with excessive production and bioactivation of transforming growth factor bets (TGF-β) in situ. Here, modification of expression of components of plasminogen/plasmin pathway in human monocytes (MN) by inhibitors of TGF-β signalling was examined. Smad3 siRNA effectively inhibited TGF-β-induced urokinase plasminogen activator receptor (uPAR). Agents known to interfere with TGF-β signalling, including the Smad inhibitors SIS3 and erythromycin derivatives, and ALK5 receptor inhibitor (SB 431542) in inhibition of uPAR expression in response to Mycobacterium tuberculosis (MTB) were examined. Inhibition by SIS3 only inhibited uPAR mRNA significantly. SIS3 may prove to be an effective adjunct to TB therapy.
© 2011 The Authors. Scandinavian Journal of Immunology © 2011 Blackwell Publishing Ltd.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22150316      PMCID： PMC3279592          DOI： 10.1111/j.1365-3083.2011.02668.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN： 0300-9475            Impact factor:   3.487


  15 in total

1.  Latency-associated peptide of transforming growth factor beta enhances mycobacteriocidal immunity in the lung during Mycobacterium bovis BCG infection in C57BL/6 mice.

Authors:  K A Wilkinson; T D Martin; S M Reba; H Aung; R W Redline; W H Boom; Z Toossi; S A Fulton
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

Review 2.  The role of TGF beta in the pathogenesis of human tuberculosis.

Authors:  Z Toossi; J J Ellner
Journal:  Clin Immunol Immunopathol       Date:  1998-05

Review 3.  TGF-beta: from latent to active.

Authors:  N Khalil
Journal:  Microbes Infect       Date:  1999-12       Impact factor: 2.700

4.  Expression of transforming growth factor-beta but not tumor necrosis factor-alpha, interferon-gamma, and interleukin-4 in granulomatous lung lesions in tuberculosis.

Authors:  H Aung; Z Toossi; S M McKenna; P Gogate; J Sierra; E Sada; E A Rich
Journal:  Tuber Lung Dis       Date:  2000

5.  Enhancement of intracellular growth of Mycobacterium tuberculosis in human monocytes by transforming growth factor-beta 1.

Authors:  C S Hirsch; T Yoneda; L Averill; J J Ellner; Z Toossi
Journal:  J Infect Dis       Date:  1994-11       Impact factor: 5.226

6.  Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549.

Authors:  L R Lund; V Ellis; E Rønne; C Pyke; K Danø
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

7.  SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7.

Authors:  Stacey DaCosta Byfield; Christopher Major; Nicholas J Laping; Anita B Roberts
Journal:  Mol Pharmacol       Date:  2004-03       Impact factor: 4.436

8.  Down-modulation of lung immune responses by interleukin-10 and transforming growth factor beta (TGF-beta) and analysis of TGF-beta receptors I and II in active tuberculosis.

Authors:  M Glória Bonecini-Almeida; John L Ho; Neio Boéchat; Richard C Huard; Sadhana Chitale; Howard Doo; Jiayuan Geng; Lorena Rego; Luiz Claudio Oliveira Lazzarini; Afrânio L Kritski; Warren D Johnson; Timothy A McCaffrey; José R Lapa e Silva
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

9.  EM703, a new derivative of erythromycin, inhibits transforming growth factor-beta signaling in human lung fibroblasts.

Authors:  ChangHe Yu; Arata Azuma; YingJi Li; Chunyan Wang; Sinji Abe; Jiro Usuki; Kuniko Matsuda; Shoji Kudoh; Toshiaki Sunazuka; Satoshi Omura
Journal:  Exp Lung Res       Date:  2008-08       Impact factor: 2.459

10.  Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542.

Authors:  N J Laping; E Grygielko; A Mathur; S Butter; J Bomberger; C Tweed; W Martin; J Fornwald; R Lehr; J Harling; L Gaster; J F Callahan; B A Olson
Journal:  Mol Pharmacol       Date:  2002-07       Impact factor: 4.436
View more
  9 in total

1.  CWHM-12, an Antagonist of Integrin-Mediated Transforming Growth Factor-Beta Activation Confers Protection During Early Mycobacterium tuberculosis Infection in Mice.

Authors:  Ninecia R Scott; Shyamala Thirunavukkarasu; Javier Rangel-Moreno; David W Griggs; Shabaana A Khader
Journal:  J Interferon Cytokine Res       Date:  2022-08-01       Impact factor: 3.657

2.  Deletion of TGF-β1 Increases Bacterial Clearance by Cytotoxic T Cells in a Tuberculosis Granuloma Model.

Authors:  Hayley C Warsinske; Elsje Pienaar; Jennifer J Linderman; Joshua T Mattila; Denise E Kirschner
Journal:  Front Immunol       Date:  2017-12-20       Impact factor: 7.561

Review 3.  Host-Directed Therapy in Tuberculosis: Targeting Host Metabolism.

Authors:  Jae-Sung Kim; Ye-Ram Kim; Chul-Su Yang
Journal:  Front Immunol       Date:  2020-08-13       Impact factor: 7.561

4.  Immune Subtyping in Latent Tuberculosis.

Authors:  Ushashi Banerjee; Priyanka Baloni; Amit Singh; Nagasuma Chandra
Journal:  Front Immunol       Date:  2021-04-07       Impact factor: 7.561

5.  The Lack of the TetR-Like Repressor Gene BCG_2177c (Rv2160A) May Help Mycobacteria Overcome Intracellular Redox Stress and Survive Longer Inside Macrophages When Surrounded by a Lipid Environment.

Authors:  Lázaro García-Morales; Patricia Del Portillo; Juan M Anzola; Miguel A Ares; Addy C Helguera-Repetto; Jorge F Cerna-Cortes; Alfonso Méndez-Tenorio; María J García; Isabel Otal; Carlos Martín; Jorge A Gonzalez-Y-Merchand; Sandra Rivera-Gutiérrez
Journal:  Front Cell Infect Microbiol       Date:  2022-07-07       Impact factor: 6.073

6.  Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment.

Authors:  Mary A De Groote; Payam Nahid; Leah Jarlsberg; John L Johnson; Marc Weiner; Grace Muzanyi; Nebojsa Janjic; David G Sterling; Urs A Ochsner
Journal:  PLoS One       Date:  2013-04-18       Impact factor: 3.240

7.  Novel targeting of PEGylated liposomes for codelivery of TGF-β1 siRNA and four antitubercular drugs to human macrophages for the treatment of mycobacterial infection: a quantitative proteomic study.

Authors:  Ning-Kui Niu; Juan-Juan Yin; Yin-Xue Yang; Zi-Li Wang; Zhi-Wei Zhou; Zhi-Xu He; Xiao-Wu Chen; Xueji Zhang; Wei Duan; Tianxin Yang; Shu-Feng Zhou
Journal:  Drug Des Devel Ther       Date:  2015-08-07       Impact factor: 4.162

8.  Identifying differentially expressed long non-coding RNAs in PBMCs in response to the infection of multidrug-resistant tuberculosis.

Authors:  Hong Yan; Rufeng Xu; Xiangrong Zhang; Qian Wang; Jing Pang; Xia Zhang; Xiaoai Chang; Yaqin Zhang
Journal:  Infect Drug Resist       Date:  2018-07-13       Impact factor: 4.003

Review 9.  Understanding the Relationship between Glutathione, TGF-β, and Vitamin D in Combating Mycobacterium tuberculosis Infections.

Authors:  Mohkam Singh; Charles Vaughn; Kayvan Sasaninia; Christopher Yeh; Devanshi Mehta; Ibrahim Khieran; Vishwanath Venketaraman
Journal:  J Clin Med       Date:  2020-08-26       Impact factor: 4.241
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.